Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Clinical trial NCT05335473 · UNKNOWN

Trial details

NCT number: NCT05335473
Sponsor: Henan Cancer Hospital
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HR Positive HER2 Negative Advanced Breast Cancer

Start date: 2022-05-13
Primary completion: 2025-05-01
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.